# Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse

> **NCT05533164** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sint Maartenskliniek** · enrollment: 174 (estimated)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05533164
- **Lead sponsor:** Sint Maartenskliniek
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-09
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05533164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05533164, "Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05533164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*